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Abstract
Pulmonary delivery of nanocarriers for novel antimycobacterial compounds is challenging because the aerodynamic proper-
ties of nanomaterials are sub-optimal for such purposes. Here, we report the development of dry powder formulations for 
nanocarriers containing benzothiazinone 043 (BTZ) or levofloxacin (LVX), respectively. The intricacy is to generate dry 
powder aerosols with adequate aerodynamic properties while maintaining both nanostructural integrity and compound activ-
ity until reaching the deeper lung compartments. Microparticles (MPs) were prepared using vibrating mesh spray drying with 
lactose and leucine as approved excipients for oral inhalation drug products. MP morphologies and sizes were measured using 
various biophysical techniques including determination of geometric and aerodynamic mean sizes, X-ray diffraction, and 
confocal and focused ion beam scanning electron microscopy. Differences in the nanocarriers’ characteristics influenced the 
MPs’ sizes and shapes, their aerodynamic properties, and, hence, also the fraction available for lung deposition. Spay-dried 
powders of a BTZ nanosuspension, BTZ-loaded silica nanoparticles (NPs), and LVX-loaded liposomes showed promising 
respirable fractions, in contrast to zirconyl hydrogen phosphate nanocontainers. While the colloidal stability of silica NPs was 
improved after spray drying, MPs encapsulating either BTZ nanosuspensions or LVX-loaded liposomes showed the highest 
respirable fractions and active pharmaceutical ingredient loads. Importantly, for the BTZ nanosuspension, biocompatibility 
and in vitro uptake by a macrophage model cell line were improved even further after spray drying.
Keywords Antibacterial nanoparticles · Benzothiazinone · Dry powder formulations · Levofloxacin · Liposomes · 
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HBSS  Hanks’ balanced salt solution
LVX  Levofloxacin
MPs  Microparticles
MTT  3-(4,5-Dimethylthiazol-2-Yl)-2, 5-diphenyl 
tetrazolium bromide
NGI  Next generation impactor
NPs  Nanoparticles
PBS  Phosphate-buffered saline
PFA  Paraformaldehyde
PMA  Phorbol 12-myristate 13-acetate
RT  Room temperature
SDS  Sodium dodecyl sulfate
SEM  Scanning electron microscopy
XRD  X-ray diffraction
Introduction
Respiratory infections and multi‑drug resistance
The mortality rate associated with microbial infections 
increases exponentially with the rate of antibiotic resistance, 
which calls for advanced therapeutic strategies to eradicate 
drug-resistant pathogens [1]. Mycobacterium tuberculosis 
(M. tuberculosis) is a serious healthcare issue due to the 
development of multi-drug resistance and difficulties in its 
complete eradication leading to high mortality [2–5]. Thus, 
the success of conventional orally administered antimicro-
bial therapies is limited. In contrast to systemically admin-
istered drugs, novel therapeutic strategies taking advantage 
of local pulmonary delivery of nanomedical formulations to 
the site of infection hold promise to overcome mycobacterial 
respiratory tract infections [2, 3].
Anti‑TB medications
Mycobacterial infections such as with M. tuberculosis have 
been a long-standing healthcare issue requiring highly potent 
medications [6, 7]. The revolution in drug discovery over 
decades brought us many lead molecules to treat such infec-
tions. Threateningly, bacteria continuously develop resist-
ances by modifying internal targets of first- and second-line 
antimycobacterial drugs via mutating [6]. More recently, 
potent new antibiotics like benzothiazinone 043 (BTZ), 
delamanid, pretomanid, and bedaquiline were developed 
against M. tuberculosis, while some of the classical antibi-
otics such as levofloxacin (LVX) and rifampicin are still used 
in the clinic [8]. However, ensuring sufficient delivery of 
these antibiotics to the site of infection is critical due to the 
drugs’ limited solubilities and unfavorable pharmacokinetic 
properties [9].
Conventional oral therapy requires high antibiotic doses 
and a continuous treatment over several months at the cost 
of patient compliance and severe side effects. Converting 
the active pharmaceutical ingredient (API) to respirable 
powders administered to the lung by inhalation has opened 
new avenues toward the treatment of grave respiratory tract 
infections [10, 11]. Such formulations can be optimized for 
improved flow properties, within a proper size range and 
aerodynamic characteristics optimal for pulmonary delivery 
[10, 11]. After deposition in the deep lungs, however, access 
to the target sites of M. tuberculosis–infected tissues is still 
limited by other biological barriers. Consequently, many 
formulations failed to exert pharmacological effects in pre-
clinical infection models. Cellular and non-cellular barriers 
encountered in the lung after deposition may hopefully be 
overcome by employing appropriate nanocarriers, whereas 
the effective delivery of nanomedicines into the lung by oral 
inhalation requires additional technological efforts.
Pulmonary nanoparticle delivery
To overcome physical constrains to pulmonary delivery, 
nanoformulations of antimycobacterial drugs must be 
administered as respirable aerosols of appropriate particle 
diameters. Nevertheless, nebulization of nanocarriers dis-
persed in aqueous media may be limited by the colloidal 
stability of such systems [12]. API-loaded nanocarriers 
embedded in dry powder microparticle (MP) formulations 
with suitable aerodynamic properties represent an approach 
to overcome this obstacle. Dry powder aerosol delivery of 
plain antimycobacterial drugs has already been successfully 
demonstrated in animal models [13–15]. However, it is not 
trivial to generate aerosol powders of accepted pharma-
ceutical excipients where nanoparticle (NP) integrity and 
aerodynamic properties are both maintained after spray dry-
ing. Indeed, high particle aggregation was noticed in many 
instances, and the occurrence of crystalline structures may 
lead to slow release and dissolution in the alveolar lining 
fluid of the deeper lung [16]. Thus, it is important to verify 
the aerodynamic properties of the spray-dried micropar-
ticulate powders, the structural integrity of the contained 
nanocarriers, as well as the release and activity of the drug 
encapsulated in the latter.
Preserving nanocarrier integrity and minimizing physico-
chemical interactions that cause particle aggregation are major 
objectives in the development of therapeutically fit dry powder 
preparations [17]. Dry powders can be prepared from suspen-
sions of nanoparticles by either spray drying or freeze drying. 
Freeze drying may result in cake formation, cracking, and dis-
ruption of the nanosystem [18], which sometimes even causes 
leakage of the cargo. In addition, it may not be possible to define 
the size and shape of the MP formulation of freeze-dried prepa-
rations [19]. Alternatively, spray drying allows to generate par-
ticles of defined size and shape, with appropriate aerodynamic 
properties for their aerosolized delivery to the lung [12, 20]. 
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However, the physicochemical properties and concentration of 
both, excipient(s) and NPs, have been demonstrated to affect the 
size and aerodynamic properties of the MPs [21].
We here developed lactose-leucine–based MPs loaded 
with various NPs and studied their principal suitability for 
lung administration. According to the literature, leucine and 
isoleucine can be used to keep the surface wetted since these 
molecules tend to stay in the interface when mixing with lac-
tose solution, thus forming a coated surface after spray drying 
[22–24]. We found that the formation of MPs by spray drying 
of lactose was indeed improved by employing the hydrophobic 
amino acid, leucine. As a result, particle aggregation was pre-
vented, and particle integrity was maintained. The MPs pro-
duced by encapsulating various kinds of NPs showed different 
morphologies, which may result from a variation in droplet 
formation with the variation in NP load. Previous reports on 
spray drying and particle formation clearly demonstrated the 
various stages in particle formation from the droplets during 
the spray-drying process [25].
This study is part of the governmentally funded multi-
disciplinary project “Antibiotic Nanocarriers for Therapeu-
tic Inhalation against Tuberculosis” (ANTI-TB). In order to 
address the obstacles sketched above, both organic (liposomal) 
and inorganic nanocarriers (silica-NPs and zirconyl hydrogen 
phosphate containers) loaded with LVX or BTZ, respectively, 
as well as some excipient-low nanosuspensions were devel-
oped by partners of this consortium. These nanoparticles were 
selected after the rigorous optimization of our partners with 
various nanosystems, antitubercular agents, drug load, and sta-
bility. Based on the investigation by the consortium partners, 
the selected best candidate in each category was taken for fur-
ther studies. Indeed, the consortium planned to have organic 
formulations (liposomal formulations from Rodos Bio Target) 
and inorganic nanocontainers (various metal oxide particles 
from KIT) and the simplest API nanosuspension; thus, we 
have selected these four different systems for this work. Based 
on these types of nanopharmaceuticals, our study focuses on 
the preparation of lactose-/leucine-based MPs with favorable 
aerodynamic properties. Besides, all dry powder formulations 
were characterized in terms of MP morphology, NP integrity, 
and colloidal stability as well as API crystallinity. Based on 
such data, the most promising candidate was further investi-
gated for biocompatibility and cellular uptake by the human 
monocytic THP-1 leukemia cell line [26].
Materials and methods
Materials
Lactose, leucine, fluorescein sodium, and LVX were 
obtained from Sigma-Aldrich, Taufkirchen, Germany. 
1-octanol was purchased from Honeywell (Fisher Scientific, 
Schwerte, Germany). The BTZ nanopharmaceuticals (NS-
BTZ and SiNP-BTZ) as well as zirconyl hydrogen phos-
phate nanocontainers (ZrNC) [27] were synthesized by the 
Feldman lab at the KIT (Karlsruhe, Germany). According 
to scanning electron microscopy and statistical evaluation, 
NS-BTZ and SiNP-BTZ NPs exhibited mean diameters and 
size distributions of 60 ± 26 nm or 53 ± 17 nm, respectively. 
In nanocontainers, BTZ had been encapsulated by a zirconyl 
hydrogen phosphate or a silica shell to disperse the lipophilic 
drug in water [27]. The ZrNC employed in this present study 
were not loaded with BTZ. Finally, LVX-loaded liposomes 
based on the patented TargoSphere® technology [28] (Lip-
TS-LVX) were formulated by Rodos Biotarget GmbH (Han-
nover, Germany). The human monocytic THP-1 leukemia 
cell line (ACC 16) was obtained from the German Collec-
tion of Microorganisms and Cell Cultures GmbH (DSMZ; 
Braunschweig, Germany).
MP formulation
Lactose solutions of 2.5% w/v were prepared by dissolv-
ing the lactose in Milli-Q water overnight using a stirrer at 
650 rpm. Further, 1 g of leucine was added to volumes of 
100 mL of the lactose solution and stirred at the same speed 
until dissolved completely. Such solutions were sterile-fil-
tered (0.45 µm) and stored in sterile containers. To prepare 
dry powder formulations of various NPs, NP suspensions 
were added to the above solutions, along with fluorescein 
sodium solution, and gently dispersed for 5 min. For the 
respective amounts and concentrations used for MP prepara-
tion, see Table 1. Using a Büchi-90 nano spray dryer (Flawil, 
Switzerland), the whole contents were spray-dried under 
the following conditions (gas flow 112 L/min, frequency 
122 kHz, inlet temperature 87 °C, outlet temperature 35 °C, 
pump 30%, spray 80%, pressure 37–38 mbar, and room 
humidity 20–30%). MPs thus gained were collected using 
a plastic scrapper, transferred to glass containers wrapped 
with aluminum foil to avoid photo bleaching, and stored in 
a desiccator at RT. For the optimization, initially, 2.5% and 
7.5% lactose particles were produced and characterized. Fur-
ther, its aerodynamic properties have been increased after 
the addition of 1% leucine in the formulation.
Characterization of dry powders
Scanning electron microscopy: Spray-dried MPs were depos-
ited gently on a carbon tape (mounted on metal stage) using 
a spatula, and a mild airflow was applied to remove loosely 
bound excess particles from the surface. Samples were then 
gold-coated (Quorum Q150R ES) and examined in a field 
emission scanning electron microscope (Zeiss EVO MA15 
 LaB6; Jena, Germany) at 5.0 kV and × 20,000 magnification.
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Static light scattering: To measure the particles’ diame-
ters via static light scattering, 20 mL of 1-octanol in a quartz 
cuvette was used as a blank in the Horiba Partica LA-960 
Laser Scattering Particle Size Distribution Analyzer (Darm-
stadt, Germany). The powders were dispersed in 1-mL 
octanol and sonicated for 1 min to achieve proper dispersion. 
Further, this suspension was gradually added to the cuvette 
containing octanol and mixed by magnetic stirring at maxi-
mum speed. The particle size distribution was calculated as 
based on the reduction in transparency and scattering values. 
Median values of each sample were plotted.
FT-IR spectroscopy: Powder samples were placed on the 
crystal of the Vertex 70 Frontier Optical FT-IR spectrometer 
(PerkinElmer, Hamburg, Germany), and the respective trans-
mittances were analyzed from 4000 to 650 wave numbers. 
As controls, samples of the non-encapsulated APIs were 
analyzed accordingly.
X-ray diffraction: Compact, thin pellets of all dry powder 
formulations (including lactose-leucine physical mixture), 
BTZ, and LVX were prepared using sample holders and sub-
sequently analyzed with an X-ray diffractometer (XʼPert Pro 
MPD, Almelo, Malvern Panalytical, The Netherlands). In 
addition, the NP control in water was analyzed to verify the 
NP-related background.
Aerodynamic properties of the dry powder 
formulations
The aerodynamic properties of the dry powder formula-
tions were measured using the COPLEY Next Generation 
Impactor (NGI) (Colwick, UK) connected with an Akita air 
flow generator (Bremen, Germany). Ten milligrams of each 
powder sample was weighted and filled in clear gelatin cap-
sules. The NGI plates were coated with polyalkylene glycol 
ether (Brij®35) + glycerol coating solution to ensure proper 
particle binding on the surface of the plate upon air circula-
tion. Capsules were placed into a HandiHaler® (Boehringer 
Ingelheim, Ingelheim, Germany) and pierced once to break 
the capsule. The inhaler was placed onto the rubber mouth-
shaped adaptor before applying pressurized air (suction) for 
4 s at a flow rate of 60 L/min. Samples deposited on all 8 
stages, pre-separator, tube, and empty capsule were collected 
using Milli-Q water. Collected samples were analyzed at 
λEX = 460 nm and λEM = 515 nm using a TECAN 96 well 
plate reader (Männedorf, Switzerland) for determining the 
amount of MP-encapsulated fluorescein. The fine particle 
fraction collected in stages 1–5 was considered as the res-
pirable fraction based on their size range (i.e., 1–5 μm). 
Exhaled powder fractions were calculated by subtracting 
the cumulative deposited particle amount in all stages, 
tube, pre-separator, and capsule from 100%. Results from 
independent experiments are depicted as means ± standard 
deviation (SD).
Stability of the nanosystem in spray‑dried powders
Confocal microscopy: Amounts of 1 mg of powder were 
admixed with 50 µL of 1-octanol and sonicated for 1 min 
for dispersion. Of these samples, aliquots of 1 μL were 
placed onto the microscopic slide and sealed with cov-
erslips. Images were taken with a Leica DMi8 Confo-
cal Microscope (Leica, Mannheim, Germany) equipped 
with a × 63 water immersion objective (HC APO CS2 
63 × /1.20) (Leica, Mannheim, Germany), and image anal-
ysis was performed with LAS X software (Leica Appli-
cation Suite X). The MPs were visualized by the green 
fluorescence of fluorescein, and the NPs were labeled with 
lumogen red in case of the inorganic NCs and PE-Texas 
Table 1  Sample designations of NPs and MPs, as well as NP and 
API contents per 15 mL of spray-drying dispersion. The yield of dry 
powder formulations was determined by weighting the powder and 
calculated as percentages of the solid content. The highest API con-
tents were achieved with BTZ-NS-MPs as a combination of both a 
high API concentration in the nanocarrier and a high particle con-
centration had been provided in the stock solution. The nanospray 
dryer uses an electrode for charge-based particle collection. Observed 
yields in the range of ~ 75–80% are plausible, since the complete col-
lection is impossible due to technical reasons













0 0 0 81
NS-BTZ (nanosuspension-benzothiazinone) NS-BTZ MPs 375 8.250 2.053/(2.983) 78
SiNP-BTZ (silica nanoparticle-benzothi-
azinone)
SiNP-BTZ MPs 1203 8.632 0.062/(2.718) 80
ZrNC (zirconyl hydrogen phosphate nanocon-
tainers)
ZrNC MPs 150 - 0/0 76
Lip-TS-LVX (TargoSphere liposome-levoflox-
acin)
Lip-TS-LVX MPs 150 1.019 0.724/(1.019) 83
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red in case of the organic NCs to determine the NP distri-
bution within the MPs.
FIB-SEM: Samples were analyzed as previously 
described [29], with slight modifications. Briefly, powders 
were dispersed in ethyl acetate and dried on a 5-mm × 5-mm 
silicon wafer under ambient conditions before the samples 
were glued on Al stubs using silver paste. An FEI Versa 3D 
FIB (Thermo Fischer, Dreieich, Germany) was used in high-
vacuum conditions to select an area (approx. 30 µm × 4 µm). 
Cross sections were prepared after deposition of ~ 2 µm Pt 
before using the Ga ion beam at 30 kV accelerating voltage 
and a 7-nA ion current. Finally, the samples were polished at 
30 kV/1 nA Ga ion beam. Cross sections of liposomes were 
visualized using secondary electron imaging (ETD detec-
tor) at 5 kV accelerating voltage. SEM imaging of the cross 
sections was also performed using an FEI Quanta 400 FEG 
(Thermo Fischer, Dreieich, Germany) under high-vacuum 
conditions. Secondary (ETD detector) and back-scattered 
(SSD detector) electron images were acquired under 52° tilt-
ing angle at 10 kV accelerating voltage.
Size and zeta potential: NP size and zeta potential were 
measured using Zetasizer Nano (Malvern Panalytical, 
Grovewood, UK). The spray-dried powders were dissolved 
in Milli-Q water, and the measurements were compared to 
the original values of the non-spray-dried nanomaterials. All 
samples were diluted for an attenuation of around  106–109. 
Three independent measurements were performed per run, 
and the SD was calculated as based on these values.
Active pharmaceutical ingredient quantification
APIs were quantified using a Dionex Ultimate 3000 U-HPLC 
(Thermo Fischer, Dreieich) equipped with a Synchronis C18 
50 × 2.1 mm, 1.7 µm column (Thermo Fischer, Germany) 
and a UV–VIS detector (Thermo Fischer, Germany). (i) In 
case of LVX, 10 mg of dry powder was dissolved in 1 mL 
PBS containing 0.1% Triton-X and eluted with a 18% of 
mobile phase A (acetonitrile (ACN)) and 72% of mobile 
phase B (0.5% trimethylamine buffer at pH 2.5) at a flow of 
0.3 mL/min (see Supporting Information, Fig. 7). (ii) In case 
of BTZ043 (Selleckchem; Houston, TX, USA), powder was 
dissolved in a 60:40 mixture of ACN:PBS at a concentration 
of 10 mg/mL of dry powder. A binary solvent gradient was 
applied at a flow rate of 0.3 mL/min and programmed as fol-
lows: 80%  H2O and 20% ACN at 0 min to 0.5 min, progress-
ing linearly at 5%  H2O and 95% ACN at 2 min, followed 
by the hold in  H2O 5% ACN to 95% for 1 min, and finally 
returning to the initial gradient until 5 min (cf. Supporting 
Information, Figs. 8 and 9). Data analysis was performed 
with Chromeleon 7 software (Thermo Fischer, Germany).
Cytotoxicity of NS‑BTZ
THP-1 cells were cultured in RPMI 1640 supplemented 
with 10% FCS during passages 16–21 and seeded in 
96-well plates (Greiner; Fisher Scientific, Germany) 
at 1 ×  105 cells/200 µL containing 25  ng/mL phorbol 
12-myristate 13-acetate (PMA), which initiates mac-
rophage differentiation [30]. Seventy-two hours post 
seeding, the cells were incubated with Hank’s balanced 
salt solution (HBSS) containing 84 μg/mL, 42 μg/mL, or 
8.4 μg/mL of dissolved NS-BTZ particles for 4 h at 37° 
and 5%  CO2. Following incubation, the cells were washed 
twice with PBS and incubated for another 4 h with 0.5 mg/
mL 3-[4, 5-dimenthylthiazol-2-yl]-2,5-diphenyl tetrazo-
lium bromide (MTT) (Sigma) in HBSS. Subsequently, 
the supernatant was removed, and formazan crystals were 
dissolved in 200 µL dimethyl sulfoxide (DMSO) (Sigma-
Aldrich). The absorbance was read at 550 nm with a Tecan 
Infinite M200Pro plate reader (Männedorf, Switzerland). 
As a control for 100% viability, the cells were incubated in 
HBSS only, whereas 1% Triton-X-treated cells served as 
a negative control (i.e., 0% viability). HBSS blanks were 
subtracted from the positive and negative controls, and 
viability percentages were calculated as
Cellular uptake
THP-1 cells were cultured as described above and seeded at 
1 ×  104 cells/well/0.5 mL in 8-well chamber slides (Greiner 
Bio-One; Kremsmünster, Austria) containing 25 mg/mL 
PMA. After 72 h, the cells were incubated for 2 h, which dis-
solved either NP or MP samples at a final BTZ043 concen-
tration of 42 µg/mL in the respective formulation. Treated 
cells were then washed twice with PBS and fixed with 4% 
paraformaldehyde (PFA) in PBS for 10 min at RT. For actin 
staining, cells were incubated for 30 min with 100 µL of 
1:1000 Alexa Fluor 488-Phalloidin stock solution (Thermo 
Fisher Scientific, Waltham, MA, USA) after permeabiliza-
tion and were blocked for 20 min with 1% w/v BSA and 
0.1% w/v saponin in PBS. Nuclei were counterstained with 
200 µL of a 1-µg/mL 4′,6-diamidino-2-phenylindole (DAPI) 
solution (Sigma-Aldrich) for 15 min. Images were taken with 
a Leica DMi8 Confocal Microscope equipped with a × 63 
water immersion objective (HC APO CS2 63 × /1.20), and 









Based on preliminary spray-drying experiments (data not 
shown), the concentrations of lactose (2.5% w/v) and leu-
cine (1.0% w/v) were considered as suitable and fixed. 
Table 1 summarizes MP designations as well as NP and 
API contents, and the obtained yields of each MP for-
mulation. Figure 1a and b depict the schematic workflow 
and structure of the different nanopharmaceuticals to be 
incorporated in MPs. The concentration of fluorescein as 
a marker compound was kept constant in all the formula-
tions, while the types and amounts of incorporated NPs 
were changed. Different physicochemical properties of the 
resulting MPs are therefore attributed to the respective 
nanomaterials used for spray drying.
The incorporation of NPs into the lactose/leucine MPs 
changed the MP’s morphological properties. Plain lac-
tose-leucine MPs (LL-MP) were round in shape (cf. Sup-
porting information, Fig. 5), having a rough surface. The 
final concentrations of lactose (2.5%) and leucine (1%) 
have been optimized based on results that indicate that 
the leucine improves the aerodynamic properties and that 
the lower lactose concentration would be advantageous 
to achieve higher drug load. (cf. Supporting information, 
Fig. 5). As shown in Fig. 1c, the shape of the LL-MPs 
was not changed considerably by incorporating NS-BTZ, 
whereas SiNP-BTZ displayed a dramatically changed mor-
phology with only few particles retaining a round shape. 
LL-MPs containing ZrNC were aggregated, whereas the 
Lip-TS-LVX formulation was changed more profoundly, 
with the occurrence of elongated structures. Morphologi-
cal changes were also reflected in the MPs’ median geo-
metric size as analyzed by static light scattering (Fig. 1d).
Although having the smallest median size, Lip-TS-LVX-
MPs showed more tailing of undersize particles compared 
to the three other MPs. However, the median size of the 
Lip-TS-LVX-MPs was not increased drastically in contrast 
to the other MPs showing increment in the median size 
compared to the plain LL-MPs. In general, with increasing 
structural complexity of the nanosystem, the median size 
of the MPs was increased. In the NS-BTZ system in which 
the API was solubilized and stabilized by sodium dodecyl 
sulfate (SDS), thus representing the “simplest” nanosystem, 
only a mild increment in particle size was observed. In con-
trast, the size of the SiNP-BTZ particles was increased evi-
dently, which corresponds to the structures visible by SEM 
Fig. 1  (A) Schematic represen-
tation on the production of MPs 
from NPs suspended in 2.5% 
lactose + 1% leucine solution. 
(B) NPs used in this study and 
their description. (C) Scanning 
electron micrographs of MPs 
(scale bar 2 µm). Characteriza-
tion of MPs by static light scat-
tering (D) and Fourier-trans-
form infrared spectroscopy (E)
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(Fig. 1c). Similarly, ZrNCs also showed a drastic increase 
in median particle size, which likewise corresponded to the 
SEM images.
Further characterization by FT-IR revealed for all the 
dry powders some peaks around 3500–3250/cm, indica-
tive of the presence of water molecules (Fig. 1e). Peaks of 
LVX or BTZ, respectively, were found merged with those 
of lactose-leucine in the corresponding dry powders. All 
powder formulations showed complex FT-IR patterns due to 
the presence of the NPs compared to the non-encapsulated 
APIs. All MP formulations were analyzed further for their 
API contents. The presence of API was measured by HPLC, 
and the loading of the selected formulations was calculated 
(Table 1). The BTZ in the nanosuspension was detected 
before and after spray drying (see Supporting information, 
Fig. 8), and the percentages of drug recovery calculated from 
these values were ~ 70% similar to the recovery of LVX from 
Lip-TS-LVX. In contrast, the BTZ content detectable in the 
SiNP-BTZ was very low (≤ 2%). However, this had already 
been observed for the same MPs before spray drying and 
may be due to a poor release from their dense, hydrophilic 
silica shell.
MP integrity after spray drying
While spray-dried MPs attained various shapes and sizes 
depending on the NP loads, the internal structural arrange-
ments of the NPs were investigated by FIB-SEM (Fig. 2a). 
Powder particles were cut to allow a view on internal struc-
tures. The plain and dense interior of the NS-BTZ was simi-
lar to that of the cargo-free plain LL-MP particles (Fig. 2a). 
SiNP-BTZ MPs were contracted and displayed some NP 
Fig. 2  (A) Characterization of various MPs by focused ion beam 
scanning electron microscopy (arrows point at the NPs inside the 
MPs; scale bar 1 µm) and confocal microscopy (scale bar 2 µm). Col-
loidal properties of the NPs before and after spray drying by measur-
ing their size (B), PDI values (C), and zeta potential (D)
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structures inside the MPs. ZrNCs were highly aggregated, 
with some hollow meshes visible on the inner surface. The 
structure of Lip-TS-LVX-MPs was also found shrunk and 
hollow (Fig. 2a).
Confocal microscopy of the various powder formula-
tions (Fig. 2a) provided further information about the NP 
distribution within the MPs. The green fluorescence signal 
from the uniformly dispersed fluorescein allows to identify 
structures of the MPs. Red fluorescence was due to Texas 
red within the NPs, and all nanocarriers revealed their 
location in the MPs. For NS-BTZ representing the small-
est and least defined nanostructures among all MP cargos, 
the particles did not become visible as distinct shapes, thus 
obviously falling below the limit of microscopic resolution 
(Fig. 2a). In contrast, the solid SiNP-BTZ were clearly vis-
ible and were well-dispersed inside the MPs (Fig. 2a). The 
Lip-TS-LVX showed some aggregation tendency (Fig. 2a), 
and aggregation was even more pronounced in case of the 
ZrNCs (Fig. 2a).
NP properties after releasing from MPs
We determined the colloidal properties of the NPs after 
being released from the MPs upon their dispersion in an 
aqueous medium. The average size of both BTZ NPs was 
reduced after spray drying, whereas the liposomal size was 
increased due to aggregation in the dissolved MP samples 
(Fig. 2b). The average size of ZrNC remained stable before 
and after spray drying. Indeed, the PDI values showed the 
same trend, which was found particularly pronounced for the 
spray-dried Lip-TS-LVX. The zeta potential of all nanocar-
riers was moderately increased after release from the spray 
dried MPs, with the most pronounced change measured for 
the Lip-TS-LVX. Although the colloidal properties follow a 
similar trend in the presence of 0.1 mg/mL simulated lung 
fluid (SLF), following the recipe described earlier [31] (cf. 
Supporting information, Fig. 6), there was slight increment 
in size and zeta potential which confirms the SLF compo-
nents did have very slight influence on the nanoparticles 
physiochemical properties in this case.
Aerodynamic properties of the MPs
Spray-dried powders were analyzed using a next-generation 
impactor (NGI) for quantification of respirable particle frac-
tions [32]. All spray-dried products showed distinct aerody-
namic properties based on their sizes, shapes, and nature of 
NP cargos as shown in Fig. 3a. The NS-BTZ MPs possessed 
good aerodynamic properties as the powder particles were 
mostly deposited in stage 2, with moderate amounts also 
recovered in stages 3–5. The amounts deposited in stages 
2–5 reflect the fraction available for deep lung deposition. 
Higher amounts of the SiNP-BTZ powders were deposited 
in stage 2 — yet less in fractions 5–8, which represent the 
exhaled portion. The depositions measured for Lip-TS-LVX 
and SiNP-BTZ were almost identical (Fig. 3a). Surprisingly, 
ZrNCs did not deposit in any of the stages, as they were 
lighter due to their high bulk volume and low density, which 
correlates with structures visible upon FIB-SEM analysis 
(Fig. 2a). In order to compare the particle fraction available 
for deep lung deposition, the cumulative deposition percent-
age from stages 1–5 was calculated and defined as respir-
able fraction (fine particle mass — FPM) [32] (Fig. 3b), 
while the material that crossed stage 8 was considered as 
exhaled fraction. The respirable fraction was thus almost 
60% in both BTZ formulations, and the exhaled fraction 
ranged between 15 and 20%. In case of the Lip-TS-LVX, 
the respirable fraction was slightly reduced, and the exhaled 
fraction was increased. Figure 3b shows the representative 
capsules after the experiment where the stickiness of the 
powders to the capsule walls corresponded to their hygro-
scopicity. The slightly stickier powder of the Lip-TS-LVX 
showed a reduced respirable fraction, while the non-adherent 
ZrNC-MPs were not recovered in any of the stages. Indeed, 
leucine played a critical role in the aerodynamic properties 
of the MPs and the absence of leucine severely affected the 
aerodynamic properties of the MPs (cf. Supporting informa-
tion, Fig. 5).
Finally, dry powders with promising respirable properties 
were checked for their crystallinity by powder X-ray diffrac-
tion measurement. The NP-free control MPs were amor-
phous (Supplementary information, Fig. 5g); this did not 
change with the addition of all three API-containing nano-
materials comprising NS-BTZ, SiNP-BTZ, and Lip-TS-LVX 
(Fig. 3c). The NPs in solution did not show any crystalline 
structure either (cf. Supporting information, Fig. 5).
Cytotoxicity and uptake studies using THP‑1 cells
As an optimal drug formulation must be biocompatible, 
it needs to be non-toxic at least within the range of the 
expected therapeutic window. We here evaluated the cyto-
toxicity of the NS-BTZ samples before and after spray dry-
ing by measuring the metabolic activity of the differentiated 
macrophage-like cells by MTT assay. Of all the formulations 
employed in this study, we selected NS-BTZ for cell interac-
tion studies because of their high fraction available for lung 
deposition, improved colloidal properties of the incorporated 
nanosystem after spray drying, and high API load. Alveolar 
macrophages, here represented by the PMA-differentiated 
human THP-1 cell line, are the predominant cell type for 
intracellular mycobacterial infections and were therefore 
selected as a model system [30, 33]. Remarkably, all spray-
dried NS-BTZ particles showed consistently reduced cyto-
toxic effects on THP-1 cells compared to the non-spray dried 
material (Fig. 4a).
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In addition, uptake by PMA-differentiated THP-1 cells of 
non-spray-dried vs. spray-dried NS-BTZ was investigated. 
Without spray drying, nanosuspensions showed aggregation 
as indicated by clusters of strong red fluorescence signals 
when offered to macrophages. In contrast, the spray-dried 
formulation showed a more homogeneously distributed and 
overall weaker red fluorescence signal of non-aggregating 
NPs when taken up by the reporter cells (Fig. 4b).
Discussion
It may be assumed that spraying of aqueous dispersions 
leads to the formation of spherical droplets. In contact with 
hot air, the water will evaporate. During this event, the 
resulting dry particles might break or shrink because of the 
pressure exerted on the surface, eventually even leading to 
asymmetric or elongated structures. Interestingly, our results 
suggest that the SiNP-BTZ were well distributed inside the 
drying droplets, while all other NPs showed some tendency 
toward aggregation. This difference might be due to differ-
ing physicochemical characteristics of the NPs incorporated 
within the resulting dry powders. During spray drying, BTZ 
nanoformulations attained colloidal stability and a dispersed 
character, which might be enabled by the lactose molecules 
coating the NPs.
The physicochemical properties of NS-BTZ and SiNP-
BTZ NPs obviously favor their homogeneous encapsula-
tion within the MPs, which appeared very similar to plain 
LL-MPs. Nevertheless, FIB-SEM analysis revealed internal 
structures within the dry powder formulations of SiNP-BTZ 
particles, while such structures were absent from the NS-
BTZ preparations. This might be due to the higher density 
and the defined nanostructure of the SiNP-BTZ, which 
allowed for its electron-microscopic detection. In con-
trast, the NS-BTZ nanosuspension of plain drug particles 
appeared to be either absorbed to the MPs’ inner lining or 
integrated within their overall structure, which in either case 
Fig. 3  (a)  Aerodynamic properties of various MPs studied by next-
generation impactor. (b) Analysis of respirable fraction calculated 
from fine particle fraction (FPF) (insert: empty capsules after comple-
tion of the NGI experiments demonstrating the variation in stickiness 
among the formulations. (c) Powder XRD measurements of the dry 
powder samples
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Fig. 4  Cytotoxicity and cell uptake of benzothiazinone 043-loaded 
nanopharmaceuticals using a macrophage-like cell line. (a) Cytotox-
icity measurement of NS-BTZ before and after spray drying (i.e., the 
dissolved NS-BTZ MP sample) using the MTT cell viability assay. 
(b) THP-1 uptake of NS-BTZ MPs analyzed by confocal micros-
copy. Nanosuspensions were labeled with lumogen red (red col-
oration), actin filaments were stained by Alexa Fluor 488-Phalloidin 
(green coloration), and nuclei were counterstained with DAPI (blue 
coloration). Frames of interest (top) have been magnified, tilted, and 
depicted three-dimensionally (bottom)
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obviously obstructs their detectability. When encapsulating 
ZrNCs or Lip-TS-LVX NPs, the MP structures were signifi-
cantly altered. Specifically, the hollow ZrNC influenced the 
aggregation considerably, and hollow spaces were observed 
inside the MPs. As mentioned in the literature [34], the 
morphology of the MPs may not be changed by the Péclet 
number but the colloidal properties of the nanosystem might 
have influenced the morphology of the MPs and the internal 
arrangements.
The aggregation of the soft Lip-TS-LVX nanosystem is 
in line with earlier findings that liposomal membrane fusion 
may occur upon their close spatial proximity inside MPs 
[25]. Despite the lactose surface coating of the liposomal 
formulation, the temperature and/or pressure exerted during 
the spray-drying process might have affected its integrity and 
fusogenicity. However, as these factors were kept constant 
for all spray-dried samples, we conclude that the observed 
MP characteristics are rather associated with the intrinsic 
chemical (composition) and physical (size) properties of the 
spray-dried nanomaterials. Furthermore, the agglomerates 
seen in the microscopic images of ZrNC was reduced when 
dissolving ZrNC-MPs in buffer. Thus, aggregation may be 
reversible and might be triggered upon reaching the pulmo-
nary mucosa. All of these characteristics certainly influenced 
the median size of the MPs and the microscopic indications 
of agglomeration indeed correlated with the MPs’ sizes as 
determined by light scattering.
In a real-world scenario, the particles’ aerodynamic prop-
erties dictate their deposition in the lung [35]. In this regard, 
the experiments employing the NGI [32] revealed that the 
BTZ formulations had almost similar aerodynamic particle-
size distributions and respirable fractions (fine particle mass: 
stages 1–5). As had been demonstrated by physicochemical 
analysis, these two particle variants exhibited similarity with 
LL-MPs and thus maintained similar aerodynamic proper-
ties. However, ZrNCs were very light, which apparently 
relates to their hollow structures. Indeed, the ZrNC NPs were 
purposefully prepared as hollow containers so as to enable 
the subsequent loading with various APIs as demonstrated 
previously [27]; this considerably influenced the density of 
the powder. As ZrNC MPs were dry and light (with a low 
density), they did not settle in any of the stages, which led to 
a significantly reduced respirable fraction. In contrast, MPs 
with a high density may have good aerodynamic properties 
and deep lung deposition. Interestingly, the observed changes 
in the shape of the Lip-TS-LVX MPs did not influence their 
aerodynamic properties, which corroborates the assumption 
that a spherical shape is not necessarily a precondition for 
optimal aerodynamic properties of a given MP.
Importantly, the FT-IR analysis revealed that non-
encapsulated BTZ and LVX were crystalline in nature, 
which was not the case for spray-dried nanocarriers con-
taining these drugs. This suggests that spray drying is also 
favorable to achieve amorphous structures [20, 36], which 
may facilitate the release of API-loaded NPs upon contact 
with the fluid of the alveolar lining. Indeed, efficient and 
rapid release of drug-loaded NPs at the site of infection is 
a prerequisite to address M. tuberculosis residing within 
infected alveolar macrophages as rapidly as possible.
Finally, both excipients — lactose [37, 38] and leucine 
[39] — are biocompatible molecules that are used as excipi-
ents in pulmonary applications. In fact, lactose is the only 
FDA-approved monosaccharide for lung applications (20, 
37, 38). The excipients employed herein are thus expected 
to aid in dispersing some of the nanocarriers while at the 
same time minimizing possible toxic effects. The stronger 
aggregation of non-spray-dried BTZ-NS might be due to 
the direct interaction of certain cellular components with 
the surface of BTZ-NS that apparently are shielded in the 
presence of lactose and leucine.
Conclusion
The physiochemical characteristics of the different nanocarri-
ers employed in this study — including size, composition, zeta 
potential, density, and their colloidal properties — influenced 
the size and aerodynamic properties of the spray-dried powders. 
Interestingly, besides potentially enabling aerosol delivery to 
the deeper lung, the colloidal properties of certain nanoformula-
tions were improved by the spray-drying process. In particular, 
the spray-dried BTZ nanosuspension showed better dispersibil-
ity and a different interaction with a macrophage-like cell line 
compared to the same nanomaterial before spray drying. While 
the colloidal properties were improved for such solid NPs post 
spray drying, soft low-density NPs tended to increase in size 
after spray drying due to some aggregation. Encouragingly, the 
relatively simple nanosuspension of plain API showed the most 
promising properties post spray drying. Such a product may be 
further evaluated in more complex biological models enabling 
to address M. tuberculosis infections more efficiently.
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